Accelerate assay development and validation with our expertise and technology in every stage of development, and Health Institution status for IVDR programs.
Experts work directly with you to customize and optimize every project and ensure your needs are met
Decades of experience developing and validating companion diagnostics for leading biotech and pharma clients
A technology-agnostic approach to enable an unbiased selection of the most suitable platforms
Specialty testing in CLIA-certified, CAP accredited, and GCLP compliant service laboratories to support concurrent clinical trials and regulatory submissions
IVDR development with Health Institution status of Discovery's laboratory confirmed by German Regional Council
One of the largest commercial fleets of proteomics, genomics, and molecular pathology instruments – all under one roof
Global standardization and harmonization of IHC assays via our Biomarker Academy™ training programs and post-approval services
Direct access to the world’s largest commercial biorepository
Our Scientists will work with you to develop the right validation for each of your projects.
Our experts develop assays, focusing on the desired outcome, to ensure precise targeting of the right patients on the right platforms. We use our large biorepository, advanced laboratory technologies, and integrated multi-omic workflows to help you understand biomarker expression and assay performance across disease indications.
We expertly measure and optimize assay performance to deliver robust assays that help accelerate your program from RUO to LDT and IVDR. We have experience validating hundreds of assays and routinely providing services spanning biomarker discovery to regulatory submission.
Discovery takes a technology-agnostic approach to enable an unbiased selection of the most suitable platforms and technologies for developing and validating diagnostic assays. This approach ensures optimal performance and accuracy, flexibility, adaptability, and the ability to leverage advancements in different technologies, leading to improved assay development and broader applicability.
Demonstration of the accuracy, sensitivity, and reproducibility of our TSO500 ctDNA NGS service Read Tech Note
How we validate IHC assays measuring sensitivity, specificity, stability and reproducibility Download Case Study
Discovery developed an assay with dynamic range, high precision and reproducibility, laying the foundation for the successful 22C3 PD-L1 companion diagnostic assay widely utilized today. Download Case Study
Discovery has been instrumental in helping determine HER2 assay design, evaluation, scoring, and clinical utility for use in breast, esophageal and gastric cancers. Download Case Study
Join Discovery Life Sciences at Phacilitate's Advanced Therapies Week 2025, Jan 20-23 in Dallas! Visit us at Booth 161 and join Dr. Yuki Maves' presentation on Jan 23. Supply Chain: […]
Join Discovery at Precision Medicine Tri-Con 2025.
Join Discovery at World CB & CDx Summit Europe 2025.
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing
